Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Athersys, Inc. (ATHX)

0.594   0.013 (2.24%) 11-28 16:00
Open: 0.5997 Pre. Close: 0.581
High: 0.6013 Low: 0.5801
Volume: 616,125 Market Cap: 10(M)

Technical analysis

as of: 2022-11-28 4:38:02 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 2.21     One year: 3.22
Support: Support1: 0.5    Support2: 0.41
Resistance: Resistance1: 1.89    Resistance2: 2.75
Pivot: 0.74
Moving Average: MA(5): 0.55     MA(20): 1.19
MA(100): 3.1     MA(250): 11.17
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 3.6     %D(3): 2.5
RSI: RSI(14): 30.4
52-week: High: 33.25  Low: 0.18
Average Vol(K): 3-Month: 1,849 (K)  10-Days: 719 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ATHX ] has closed above bottom band by 41.7%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.6 - 0.6 0.6 - 0.61
Low: 0.57 - 0.58 0.58 - 0.58
Close: 0.59 - 0.59 0.59 - 0.6

Company Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Headline News

Wed, 23 Nov 2022
Athersys CEO Trades $54K In Company Stock - Athersys (NASDAQ:ATHX) - Benzinga

Tue, 15 Nov 2022
Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update - Business Wire

Fri, 11 Nov 2022
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference - Business Wire

Wed, 09 Nov 2022
Athersys may 'need to cease operations' if debt restructuring fails - The Business Journals

Tue, 08 Nov 2022
Healthcare Stocks on the Move Tuesday: NEO, ADAP, OCUP, ONCY, BVS, RCM, ATHX, NRBO - InvestorsObserver

Tue, 08 Nov 2022
Athersys Shares Slide Premarket on Public Offering Plans >ATHX - MarketWatch

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -41 (M)
Shares Float 0 (M)
% Held by Insiders 1.22e+007 (%)
% Held by Institutions 9.34e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.557e+007
EPS Est Next Qtl -0.08
EPS Est This Year -0.24
EPS Est Next Year -0.31
Book Value (p.s.) -0.36
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 451.5
Return on Equity (ttm) -101.5
Qtrly Rev. Growth 276
Gross Profit (p.s.) -5.38
Sales Per Share 0.88
EBITDA (p.s.) -6.39
Qtrly Earnings Growth -8.56e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -1.67
Price to Sales 0.67
Price to Cash Flow 0

Stock Dividends

Dividend 633280
Forward Dividend 851030
Dividend Yield 106613000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.